1 recruiting. 1 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Early Phase 1 | 1 | Recruiting 1 |
Follow Tan Jie: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Efficacy of PRG-2302 for Refractory or Relapsed B-cell Acute Lymphoblastic Leukemia Disease. PRG2302 - Acute Lymphoblastic Leukemia | Early Phase 1 | Recruiting | Tan Jie | 18 | 2024-05-24 | 2024-10-26 |
Precursor Cell Lymphoblastic Leukemia-Lymphoma (1)
China (1)